Vivus Announces Enrollment Of First Patient In Phase 2 Clinical Trial Assessing Ethanol-Free Carmustine As A Component Of High-Dose Chemotherapy Prior To Transplant In Patients With Hodgkin Or Non-Hodgkin Lymphoma
ReutersApr 14, 2025 2:16 PM
April 14 (Reuters) -
VIVUS ANNOUNCES ENROLLMENT OF FIRST PATIENT IN PHASE 2 CLINICAL TRIAL ASSESSING ETHANOL-FREE CARMUSTINE AS A COMPONENT OF HIGH-DOSE CHEMOTHERAPY PRIOR TO TRANSPLANT IN PATIENTS WITH HODGKIN OR NON-HODGKIN LYMPHOMA
Further company coverage: [ ]
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Related Articles
Meta’s Big Bet: Soaring Profits, Sky-High Risks
TradingKey - Meta's (META) Q1 2025 earnings come in with the world watching in scrutiny. The company has established itself as a platform that exists at the intersection of AI infrastructure, hardware innovation, and next-wave advertising.TradingKey
10 hours ago
What is a Spot ETF for Altcoins? Which Tokens Might the SEC Approve for Spot ETFs?
a spot ETF for altcoins tracks the prices of altcoins and can be traded on stock exchanges. Once approved, these ETFs will be listed on platforms like Nasdaq and the New York Stock Exchange, not just on cryptocurrency exchanges like Coinbase and Binance.TradingKey
12 hours ago
Understanding the U.S. Fiscal Framework: Is Trump’s Tariff-for-Tax-Cut Strategy Viable?
TradingKey – With the U.S. Senate and House of Representatives passing the budget resolution for President Donald Trump's second administration (Trump 2.0), his fiscal blueprint—centered on tax cuts, slashing government spending, and debt reduction—is moving forward. However, with federal debt at...TradingKey
13 hours ago
Buffett’s Billion-Yen Bet: Why Global Capital Is Flowing Into Japan
TradingKey - Since April, the Nikkei 225 has surged from 32,000 to nearly 38,000 points—a 15% gain that sharply outpaces the S&P 500’s performance over the same period. Beyond the uptick in local investor engagement, global funds have also renewed their interest in Japan’s markets.TradingKey
14 hours ago
